Herantis aims to present research results during the autumn four

Drug developer Use pharmaceutical announced its financial statements in the morning. The company has no turnover yet.

In July -December, the other income of Herantis’ business was EUR 0.6 million, compared with EUR 5.0 million during the comparison period. The result was EUR 2.3 million at a loss, compared with EUR 2.1 million a year earlier.

In July, Herantis announced that The Michael J. Fox Foundation for Parkinson’s Research and The Parkinson’s Virtual Biotech will jointly fund the Her-096 phase 1B clinical study and the ongoing biomarker survey with a total of EUR 3.6 million research funding.

The main objective of the ongoing clinical examination of the past 1B of Herantis is to show that repeated subcutaneous doses of the HER-096 examination drug are safe and well-tolerated in patients with Parkinson’s disease.

The permit application for a clinical study was approved in September, the dosing of Her-096 began in October and the first part of the study was successfully completed in November.

In January, Herantis started dosing to the first Parkinson’s patient. The company aims to present the key results of the study in the third quarter.

“Considering promising results from a previous study of CDNF phase 1, which found signs of both clinical and biological effects in highly advanced Parkinson’s patients, we are now looking forward to the main results of the study in the third quarter of 2025,” CEO Antti Vuolanto Comment on the financial statements.

Herantis raised EUR 5.2 million at the beginning of February with directed Ann.